Curis and Debiopharm Report Preclinical Data for Debio 0932

Curis, Inc. and Debiopharm Group™ have announced the presentation of data for Debio 0932 at the Annual Meeting of the American Association for Cancer Research (AACR) that demonstrated synergy between Debio 0932 and various standard of care (SOC) agents in multiple in vitro and xenograft models of non-small cell lung cancer (NSCLC) and renal cell carcinoma (RCC).

Debio 0932 is currently being investigated in a Phase 1/2 trial in combination with SOC agents in patients with advanced NSCLC and in Phase 1 trial in combination with everolimus, a mTOR inhibitor in advanced RCC patients.

In a high throughput combination screen performed with six different human NSCLC cell lines, Debio 0932 demonstrated consistent synergy with microtubule and mTOR/ Akt targeting agents across all six cell lines.

Additionally, Debio 0932 also showed strong synergy with everolimus in multiple patient derived and conventional RCC cell lines. Similar synergy and anti-tumor activity with Debio 0932 in combination with these agents was also demonstrated in human xenograft models of NSCLC and RCC.

“We are very encouraged by these preclinical data, which are the basis for the ongoing trials in NSCLC and RCC with Debio 0932 in combination with respective SOC agents,” said Rolland-Yves Mauvernay, President and founder of Debiopharm Group™.

“These preclinical combination treatment results with multiple agents provide the path and strong rationale for clinical investigation of Debio 0932 in combination with SOC therapies that may provide improved benefit for patients with advanced lung and kidney cancers,” said Ali Fattaey, Ph.D., President and Chief Operating Officer of Curis.